ATE420179T1 - Identifizierung des plasmodium falciparum erythrozyt membranprotein 1 (pfemp1) gebietes, das adhäsion zum chondroitin sulfat a vermittelt - Google Patents

Identifizierung des plasmodium falciparum erythrozyt membranprotein 1 (pfemp1) gebietes, das adhäsion zum chondroitin sulfat a vermittelt

Info

Publication number
ATE420179T1
ATE420179T1 AT00961513T AT00961513T ATE420179T1 AT E420179 T1 ATE420179 T1 AT E420179T1 AT 00961513 T AT00961513 T AT 00961513T AT 00961513 T AT00961513 T AT 00961513T AT E420179 T1 ATE420179 T1 AT E420179T1
Authority
AT
Austria
Prior art keywords
chondroitin sulfate
pfemp1
identification
area
membrane protein
Prior art date
Application number
AT00961513T
Other languages
English (en)
Inventor
Arthur Scherf
Louis Miller
Benoit Gamain
Dror Baruch
Pierre Buffet
Christine Scheidig
Jurg Gysin
Bruno Pouvelle
Nbbutaka Fujii
Joseph Smith
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE420179T1 publication Critical patent/ATE420179T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
    • G01N2333/445—Plasmodium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00961513T 1999-09-01 2000-09-01 Identifizierung des plasmodium falciparum erythrozyt membranprotein 1 (pfemp1) gebietes, das adhäsion zum chondroitin sulfat a vermittelt ATE420179T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15202399P 1999-09-01 1999-09-01

Publications (1)

Publication Number Publication Date
ATE420179T1 true ATE420179T1 (de) 2009-01-15

Family

ID=22541238

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00961513T ATE420179T1 (de) 1999-09-01 2000-09-01 Identifizierung des plasmodium falciparum erythrozyt membranprotein 1 (pfemp1) gebietes, das adhäsion zum chondroitin sulfat a vermittelt

Country Status (7)

Country Link
US (1) US6855323B2 (de)
EP (1) EP1212423B1 (de)
AT (1) ATE420179T1 (de)
AU (1) AU7345500A (de)
DE (1) DE60041340D1 (de)
DK (1) DK1212423T3 (de)
WO (1) WO2001016326A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703386D0 (sv) * 1997-09-19 1997-09-19 Karolinska Innovations Ab Malaria polypeptides
EP1284995A2 (de) * 2000-05-31 2003-02-26 Institut Pasteur Proteine, die and der zelladhäsion von plasmodium falciparum ring-stadien infizierten erythrocyten beteiligt sind
WO2002066515A1 (en) * 2001-02-23 2002-08-29 Institut Pasteur Generation of monoclonal antibodies to poorly immunogenic antigens expressed or carried by eukaryotic cells, use of monoclonal antibodies for therapeutical, diagnostic or vaccine applications
EP1590368B1 (de) 2003-01-27 2014-02-26 Københavns Universitet Verbindung brauchbar für die diagnose und behandlung von schwangerschaftsassoziierter malaria
US20090130136A1 (en) * 2004-09-30 2009-05-21 Miller Louis H Chondroitin Sulphate a Binding Domains
DE602006015985D1 (de) 2005-09-30 2010-09-16 Philadelphia Health & Educatio Antigene gegen das leberstadium von plasmodium
CN102618538B (zh) * 2011-01-26 2015-05-20 中国人民解放军第二军医大学 一种调控真核生物基因转录的dna序列及其结合蛋白
SG10201606195UA (en) * 2012-02-09 2016-09-29 Var2 Pharmaceuticals Aps Targeting of chondroitin sulfate glycans
HU230341B1 (hu) 2012-04-20 2016-02-29 Advancell Diagnosztika Kft. A vörösvérsejt-membrán kvantitatív biomarkerei
CN109387627B (zh) * 2018-10-16 2021-09-24 中国科学院深圳先进技术研究院 一种基于胎盘样硫酸软骨素a的癌症筛查和早期诊断的试剂方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
US5993827A (en) * 1993-09-10 1999-11-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Binding domains from plasmodium vivax and plasmodium falciparum erythrocyte binding proteins

Also Published As

Publication number Publication date
US6855323B2 (en) 2005-02-15
DE60041340D1 (de) 2009-02-26
EP1212423B1 (de) 2009-01-07
DK1212423T3 (da) 2009-04-27
WO2001016326A2 (en) 2001-03-08
WO2001016326A3 (en) 2001-08-23
EP1212423A2 (de) 2002-06-12
US20040062769A1 (en) 2004-04-01
AU7345500A (en) 2001-03-26

Similar Documents

Publication Publication Date Title
DE69006018T3 (de) Impfung und methoden gegen krankheiten, die von pathologischen reaktionen der spezifischen t-zellen abstammen.
HK1081598A1 (en) Treatment of huntington's disease with epa
NO963239D0 (no) Klorpyrimid-mellomprodukter
ATE420179T1 (de) Identifizierung des plasmodium falciparum erythrozyt membranprotein 1 (pfemp1) gebietes, das adhäsion zum chondroitin sulfat a vermittelt
EP0554383A4 (de)
FR2703693B1 (fr) Procédé rapide de détermination d'une séquence d'ADN et application au séquençage et au diagnostic.
GR3005272T3 (de)
WO2003105725A3 (en) ARTIFICIAL CORNEA
WO2004028341A3 (en) Susceptibility gene for human stroke; methods of treatment
WO2002044736A3 (en) Diagnosis and treatment of epidermal or skin diseases
WO2001036465A3 (en) Human zven proteins
ES8707565A1 (es) Un procedimiento para producir un anticuerpo monoclonal
MX9304070A (es) Piperidilamidas, piperidilsulfonamidas y piperidilsulfoxamidas novedosas como inhibidores de la biosintesis del colesterol.
FR2802678B1 (fr) Systeme et procede d'analyse et de simulation previsionnelle de l'evolution temporelle d'une zone pileuse, et plus particulierement du cuir chevelu humain
WO2001029070A8 (en) Modulation of t cell differentiation for the treatment of t helper cell mediated diseases
CA2385872A1 (en) Gene transfer in human lymphocytes using retroviral scfv cell targeting
IT8519118A0 (it) Procedimento per la produzione di colture di tessuti mixotrofiche e piante resistenti agli erbicidi.
FR2600655B1 (fr) Fraction proteique extraite des activites facteurs de croissance, obtention et application comme agent de stimulation et de potentialisation des activites facteurs de croissance
ATE275207T1 (de) Dna zur abschätzung des progressionspotentials von zervixläsionen
DE60029939D1 (de) Diagnosisverfahren für whipples krankheit
FR2767537B1 (fr) Gene codant pour l'androctonine, vecteur le contenant et plantes transformees obtenues resistantes aux maladies
FR2837833B1 (fr) Procede de culture en masse, de la diatomee "haslea ostrearia simonsen" et utilisation des cultures obtenues par le procede
MY143222A (en) Expression vector for animal cell
DE3687448T2 (de) Verwendung von 6h-7,8-dihydrothiapyrano(3,2d)pyrimidinen zur herstellung von arzneimitteln zur verwendung als hypoglykaemische mittel oder als abmagerungsmittel fuer fettsuechtige patienten.
ATE100111T1 (de) Impfung und methoden gegen krankheiten, die von pathologischen reaktionen der spezifischen tzellen abstammen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties